O. Tournilhac

Discipline

Sociologie (1) Psychologie (1) Economies et finances (1)

Type de document

Articles (7)

Co-auteur

Date

Source

Mot-clé

Lymphomas (6) Treatment (5) Patients (5) Human beings (5) Patients (5) thérapie (4) maladie (4) survie (4) Cases (4) Therapeutics (4) Survival (4) Cases (4) maladie (4) Chemotherapy (3) Impact (3) Expression (3) Chemotherapy (3) Use (3) risque (2) gène (2) Genes (2) Rates (2) Tumors (2) Risk (2) Performance (2) Multivariate analysis (2) French (2) Older people (2) Addition (2) Utilization (2)

Documents écrit par O. Tournilhac (7) | parle de O. Tournilhac (0)

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.
C. Bonnet et al. (1 juin 2023)
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
L. Veloza et al. (1 janv. 2023)
Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma.
K. Laribi et al.
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
L. Adès et al.
Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.
D. Vallois et al. (2016)
Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets.
L. de Leval et al. (2015)
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
C. Bossard et al. (6 nov. 2014)